Format

Send to

Choose Destination
Lancet Oncol. 2016 Apr;17(4):e149-e162. doi: 10.1016/S1470-2045(15)00545-8. Epub 2016 Mar 29.

Paediatric extracranial germ-cell tumours.

Author information

1
Division of Haematology and Oncology, The Hospital for Sick Children and the University of Toronto, Toronto, ON, Canada. Electronic address: furqan.shaikh@sickkids.ca.
2
Department of Pathology, University of Cambridge, Cambridge, UK; Department of Paediatric Haematology and Oncology, Addenbrooke's Hospital, Cambridge, UK.
3
Department of Pediatrics, Department of Molecular Biology and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Gill Center for Cancer and Blood Disorders, Children's Health, Dallas, TX, USA.
4
Department of Pathology, University of Cambridge, Cambridge, UK; Department of Histopathology, Addenbrooke's Hospital, Hills Road, Cambridge, UK.
5
Department of Paediatric Haematology and Oncology, Addenbrooke's Hospital, Cambridge, UK.
6
Royal Victoria Infirmary NHS Foundation Trust, Newcastle upon Tyne, UK.
7
Yale University School of Medicine, New Haven, CT, USA.
8
University College London Hospitals NHS Foundation Trust, London, UK.
9
Division of Pediatric Epidemiology and Clinical Research and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
10
Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA.
11
Riley Hospital for Children, Indianapolis, IN, USA.
12
Leeds Institute of Cancer and Pathology, University of Leeds, UK.
13
Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA, USA.

Erratum in

Abstract

Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.

PMID:
27300675
DOI:
10.1016/S1470-2045(15)00545-8
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for White Rose Research Online
Loading ...
Support Center